Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Cheng Lei China: Jailed Australian TV anchor jailed releases rare messageChina's 'core socialist values' daubed on a London wall inspire war of wordsBeijing confirms missing Taiwan publisher Li Yanhe is under national security investigationWatch: Auckland teens rescued from rocks as water 'rapidly' rose around themOne dead in Northland crashChina is drilling some of the deepest holes in hunt for natural resourcesShi Fu Miz 2023: Hong Kong music & art festival returns to Cheung Chau farm, expands to 3 daysBrick Lane: Chinese political slogans appear on famous London streetRussia election: Arrests for vandalism as ballot boxes targeted in Putin voteSo, you want to be an MP? These are the careers most likely to lead to Parliament